Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T11:28:34.390Z Has data issue: false hasContentIssue false
  • English
  • Français

The Economic Burden of Hospital-Acquired Clostridium difficile Infection: A Population-Based Matched Cohort Study

Published online by Cambridge University Press:  20 June 2016

Natasha Nanwa ,
Jeffrey C. Kwong ,
Murray Krahn ,
Nick Daneman ,
Hong Lu ,
Peter C. Austin ,
Anand Govindarajan ,
Laura C. Rosella ,
Suzanne M. Cadarette  and
Beate Sander
Natasha Nanwa*
Affiliation:
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada Toronto Health Economics and Technology Assessment Collaborative, Toronto, Canada
Jeffrey C. Kwong
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada Dalla Lana School of Public Health, University of Toronto, Toronto, Canada University Health Network, Toronto, Canada Department of Family and Community Medicine, University of Toronto, Toronto, Canada Public Health Ontario, Toronto, Canada
Murray Krahn
Affiliation:
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada Toronto Health Economics and Technology Assessment Collaborative, Toronto, Canada Institute for Clinical Evaluative Sciences, Toronto, Canada University Health Network, Toronto, Canada Department of Medicine, University of Toronto, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
Nick Daneman
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada Department of Medicine, University of Toronto, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada Sunnybrook Health Sciences Centre, Toronto, Canada
Hong Lu
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada
Peter C. Austin
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada Sunnybrook Health Sciences Centre, Toronto, Canada
Anand Govindarajan
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada Mount Sinai Hospital, Toronto, Canada Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Canada
Laura C. Rosella
Affiliation:
Institute for Clinical Evaluative Sciences, Toronto, Canada Dalla Lana School of Public Health, University of Toronto, Toronto, Canada Public Health Ontario, Toronto, Canada
Suzanne M. Cadarette
Affiliation:
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada Institute for Clinical Evaluative Sciences, Toronto, Canada
Beate Sander
Affiliation:
Toronto Health Economics and Technology Assessment Collaborative, Toronto, Canada Institute for Clinical Evaluative Sciences, Toronto, Canada Public Health Ontario, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
*
Address correspondence to Natasha Nanwa, MSc, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, 6th Fl, Rm 658, Toronto, Ontario, M5S 3M2, Canada ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

BACKGROUND

High-quality cost estimates for hospital-acquired Clostridium difficile infection (CDI) are vital evidence for healthcare policy and decision-making.

OBJECTIVE

To evaluate the costs attributable to hospital-acquired CDI from the healthcare payer perspective.

METHODS

We conducted a population-based propensity-score matched cohort study of incident hospitalized subjects diagnosed with CDI (those with the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Canada code A04.7) from January 1, 2003, through December 31, 2010, in Ontario, Canada. Infected subjects were matched to uninfected subjects (those without the code A04.7) on age, sex, comorbidities, geography, and other variables, and followed up through December 31, 2011. We stratified results by elective and nonelective admissions. The main study outcomes were up-to-3-year costs, which were evaluated in 2014 Canadian dollars.

RESULTS

We identified 28,308 infected subjects (mean annual incidence, 27.9 per 100,000 population, 3.3 per 1,000 admissions), with a mean age of 71.5 years (range, 0–107 years), 54.0% female, and 8.0% elective admissions. For elective admission subjects, cumulative mean attributable 1-, 2-, and 3-year costs adjusted for survival (undiscounted) were $32,151 (95% CI, $28,192–$36,005), $34,843 ($29,298–$40,027), and $37,171 ($30,364–$43,415), respectively. For nonelective admission subjects, the corresponding costs were $21,909 ($21,221–$22,609), $26,074 ($25,180–$27,014), and $29,944 ($28,873–$31,086), respectively.

CONCLUSIONS

Hospital-acquired CDI is associated with substantial healthcare costs. To the best of our knowledge, this study is the first CDI costing study to present longitudinal costs. New strategies may be warranted to mitigate this costly infectious disease.

Infect Control Hosp Epidemiol 2016;37:1068–1078

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 37 , Issue 9 , September 2016 , pp. 1068 - 1078
Copyright
© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Lessa, FC, Mu, Y, Bamberg, WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–834.Google Scholar
2. Kwong, JC, Ratnasingham, S, Campitelli, MA, et al. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLOS ONE 2012;7:e44103.Google Scholar
3. Badger, VO, Ledeboer, NA, Graham, MB, Edmiston, CE Jr. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 2012;36:645–662.Google Scholar
4. Dubberke, ER, McMullen, KM, Mayfield, JL, et al. Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease? Infect Control Hosp Epidemiol 2009;30:332–337.Google Scholar
5. Dubberke, ER, Reske, KA, Yan, Y, Olsen, MA, McDonald, LC, Fraser, VJ. Clostridium difficile–associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543–1549.Google Scholar
6. Hensgens, MP, Goorhuis, A, Dekkers, OM, Kuijper, EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012;67:742–748.Google Scholar
7. Vardakas, KZ, Polyzos, KA, Patouni, K, Rafailidis, PI, Samonis, G, Falagas, ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012;40:1–8.Google Scholar
8. Musher, DM, Nuila, F, Logan, N. The long-term outcome of treatment of Clostridium difficile colitis. Clin Infect Dis 2007;45:523–524.Google Scholar
9. Halabi, WJ, Nguyen, VQ, Carmichael, JC, Pigazzi, A, Stamos, MJ, Mills, S. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg 2013;217:802–812.Google Scholar
10. Ananthakrishnan, AN, McGinley, EL, Saeian, K, Binion, DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:976–983.CrossRefGoogle ScholarPubMed
11. Karas, JA, Enoch, DA, Aliyu, SH. A review of mortality due to Clostridium difficile infection. J Infect 2010;61:1–8.Google Scholar
12. Nanwa, N, Kendzerska, T, Krahn, M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 2015;110:511–519.Google Scholar
13. Institute for Clinical Evaluative Sciences (ICES). ICES data. ICES website. http://www.ices.on.ca/Data-and-Privacy/ICES-data. Published 2014. Accessed August 29, 2014.Google Scholar
14. Wilcox, MH, Cunniffe, JG, Trundle, C, Redpath, C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23–30.Google Scholar
15. Campbell, R, Dean, B, Nathanson, B, Haidar, T, Strauss, M, Thomas, S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ 2013;16:440–448.Google Scholar
16. Austin, PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150–161.Google Scholar
17. Austin, PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.Google Scholar
18. Wodchis, WP, Bushmeneva, K, Nikitovic, M, McKillop, I. Guidelines on Person-Level Costing Using Administrative Databases in Ontario Working Paper Series. Vol. 1 Toronto: Health System Performance Research Network, 2013.Google Scholar
19. Austin, PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res 2011;46:119–151.Google Scholar
20. Agresti, A, Min, Y. Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data. Stat Med 2004;23:65–75.CrossRefGoogle ScholarPubMed
21. Austin, PC, Small, DS. The use of bootstrapping when using propensity-score matching without replacement: a simulation study. Stat Med 2014;33:4306–4319.Google Scholar
22. Brown, ML, Riley, GF, Potosky, AL, Etzioni, RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249–1259.Google Scholar
23. Yabroff, KR, Lamont, EB, Mariotto, A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–641.CrossRefGoogle ScholarPubMed
24. Riley, GF, Potosky, AL, Lubitz, JD, Kessler, LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–841.Google Scholar
25. Krajden, M, Kuo, M, Zagorski, B, Alvarez, M, Yu, A, Krahn, M. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010;24:717–726.Google Scholar
26. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies. CADTH website. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Published 2006. Accessed June 9, 2015.Google Scholar
27. Bank of Canada. Annual average exchange rates. Bank of Canada website. http://www.bankofcanada.ca/rates/exchange/annual-average-exchange-rates/. Published 2014. Accessed June 9, 2015.Google Scholar
28. Juurlink, D PC, Croxford, R, Chong, A, Austin, P, Tu, J, Laupacis, A. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto: Institute for Clinical Evaluative Sciences, 2006.Google Scholar
29. Wijeysundera, HC, Machado, M, Wang, X, et al. Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. Value Health 2010;13:915–921.Google Scholar
30. Thein, H-H, Isaranuwatchai, W, Campitelli, MA, et al. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 2013;58:1375–1384.CrossRefGoogle ScholarPubMed
31. The Organisation for Economic Co-operation and Development (OECD). PPPs and exchange rates. OECD website. http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4. Published 2014. Accessed July 14, 2014.Google Scholar
32. Bank of Canada. Inflation Calculator. Bank of Canada website. http://www.bankofcanada.ca/rates/related/inflation-calculator/. Published 2014. Accessed July 14, 2014.Google Scholar
33. Pillai, DR, Longtin, J, Low, DE. Surveillance data on outbreaks of Clostridium difficile infection in Ontario, Canada, in 2008-2009. Clin Infect Dis 2010;50:1685–1686.Google Scholar
34. Yasunaga, H, Horiguchi, H, Hashimoto, H, Matsuda, S, Fushimi, K. The burden of Clostridium difficile-associated disease following digestive tract surgery in Japan. J Hosp Infect 2012;82:175–180.Google Scholar
35. Zerey, M, Paton, BL, Lincourt, AE, Gersin, KS, Kercher, KW, Heniford, BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007;8:557–566.Google Scholar
36. Hensgens, MPM, Goorhuis, A, Dekkers, OM, van Benthem, BHB, Kuijper, EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013;56:1108–1116.Google Scholar
37. Bhangu, S, Bhangu, A, Nightingale, P, Michael, A. Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. Colorectal Dis 2010;12:241–246.CrossRefGoogle ScholarPubMed
38. Pepin, J, Valiquette, L, Cossette, B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037–1042.Google Scholar
39. Dubberke, ER, Reske, KA, Olsen, MA, McDonald, LC, Fraser, VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008;46:497–504.CrossRefGoogle Scholar
40. Negron, M, Barkema, H, Rioux, K, et al. Accuracy of ICD-9 and ICD-10 codes for Clostridium difficile among ulcerative colitis patients. Am J Gastroenterol 2011;106:S481.Google Scholar
41. Mitchell, BG, Gardner, A, Barnett, AG, Hiller, JE, Graves, N. The prolongation of length of stay because of Clostridium difficile infection. Am J Infect Control 2014;42:164–167.Google Scholar
Supplementary material: File

Nanwa supplementary material

Figure S1 and Tables S1-S8

Download Nanwa supplementary material(File)
File 1.6 MB